InMed Pharmaceuticals (INM) Income from Continuing Operations (2021 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Income from Continuing Operations of 2791751.0 for Q1 2026, down 35.06% year-over-year from 4298866.09 in Q1 2025, and down 37.65% quarter-over-quarter from 2028223.0 in Q4 2025.
InMed Pharmaceuticals (INM) Income from Continuing Operations (2021 - 2026) Analysis & Trends
InMed Pharmaceuticals' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 2791751.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 35.06% year-over-year to 2791751.0; the TTM figure through Mar 2026 stood at 7853314.0 (up 4.81% YoY), while the FY2025 annual figure was 8162133.0, down 6.34% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 2791751.0, down from 2028223.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 336591.0 in Q2 2023, with the low at 7870023.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 2028223.0 (2025), against an average of 2419337.35.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations soared 95.72% in 2023, then slumped 473.57% in 2024.
- InMed Pharmaceuticals' Income from Continuing Operations stood at 2098087.0 in 2022, then advanced by 29.55% to 1478185.0 in 2023, then slumped by 74.2% to 2575024.0 in 2024, then advanced by 21.23% to 2028223.0 in 2025, then plunged by 37.65% to 2791751.0 in 2026.
- Business Quant data shows INM's Income from Continuing Operations at 2791751.0 in Q1 2026, 2028223.0 in Q4 2025, and 1726899.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.52 Mn | 1.28 Mn | - | -2.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.79 Mn |
| Dec 31, 2025 | -2.03 Mn |
| Sep 30, 2025 | -1.73 Mn |
| Jun 30, 2025 | -1.31 Mn |
| Mar 31, 2025 | -2.07 Mn |
| Dec 31, 2024 | -2.58 Mn |
| Sep 30, 2024 | -1.68 Mn |
| Jun 30, 2024 | -1.93 Mn |
| Mar 31, 2024 | -1.72 Mn |
| Dec 31, 2023 | -1.48 Mn |
| Sep 30, 2023 | -2.54 Mn |
| Jun 30, 2023 | -336,591.00 |
| Mar 31, 2023 | -2.00 Mn |
| Dec 31, 2022 | -2.10 Mn |
| Sep 30, 2022 | -3.51 Mn |
| Jun 30, 2022 | -7.87 Mn |
| Mar 31, 2022 | -3.48 Mn |
| Dec 31, 2021 | -4.28 Mn |
| Sep 30, 2021 | -2.97 Mn |